Dori Pelled

VP R&D
Pharma
Eloxx Pharmaceuticals
Israel

Business Expert Clinical Sciences
Biography

Dr. Pelled brings to Eloxx over 15 years of experience in the biotech industry. Prior to joining Eloxx, he headed the preclinical research and development at Chiasma Pharmaceuticals Ltd. (NASDAQ:CHMA), a drug company that redevelops poorly-absorbed small molecules into oral drugs, and at NiTi Surgical Solutions, a medical device company that focused on implants for gastrointestinal surgery. Prior to NiTi, he was responsible for clinical research and for the developing of new molecules in the medical food company, Enzymotec (NASDAQ:ENZY), where he served as the Director of Clinical Studies and as the CTO. Dr. Pelled has published over 25 original papers in peer-reviewed journals and he holds 15 patents. He received his PhD in Biochemistry from the Weizmann Institute of Science, and obtained BSc and MSc degrees in Chemistry and Clinical Biochemistry from the Tel-Aviv University.

Research Intrest

Healthcare

Global Scientific Words in Clinical Sciences